SCHEMBL17093429

SCHEMBL17093429

CN(N=C(c1ccccc1)c1ccccc1)C(=N)NO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.42
▸ CTSK P43235 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ HPGD P15428 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ HDAC1 Q13547 2/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.36
▸ HDAC3 O15379 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ NCOR2 Q9Y618 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7203350 0.79 HDAC3 (0.35) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL10498731 0.72 ALDH1A1 (0.50) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL17093430 0.70 CTSL (0.51) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL15616898 0.70 CTSL (0.51) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL11836946 0.67 LMNA (0.48) ALDH1A1HDAC1CA12CA1CA9
SCHEMBL11699938 0.67 ALDH1A1 (0.50) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL15549217 0.64 ALDH1A1 (0.47) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL4379211 0.64 G6PC1 (0.50) CTSLCTSKALDH1A1HPGDGFER
SCHEMBL8087997 0.63 ALDH1A1 (0.70) ALDH1A1HPGDGFERALOX15HSD17B10
Bromide SCHEMBL7203345 0.63 ALDH1A1 (0.47) CTSLCTSKALDH1A1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240276957-A1 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. 2024-08-22 — — US disclosed
WO-2020247819-A2 METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS AGIOS PHARMACEUTICALS, INC. (US) 2020-12-10 — — WO disclosed
EP-2877457-B1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS INC (US) 2020-09-23 — — EP disclosed
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2017-11-16 — — US disclosed
US-9725426-B2 Cystathionine-γ-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. (US) 2017-08-08 — — US disclosed
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS SOVA PHARMACEUTICALS, INC. 2015-10-01 — — US disclosed
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS SOVA PHARMACEUTICALS, INC. 2015-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327478-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTSL 1648/4885CTSK 1364/4885ALDH1A1 954/4885
US-20150266837-A1 CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS CBS, CTH, BHMT CTSL 1648/4885CTSK 1364/4885ALDH1A1 954/4885
US-20150272934-A1 USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS HIF1AN, CBS, COXFA4L2 CTSL 1340/4885CTSK 612/4885ALDH1A1 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback